Get started
Author

Freddy Elad Essogmo

Observed name: Essogmo Freddy Elad
ORCID: 0009-0003-0857-5423
Observed ORCID: 0009-0003-0857-5423
OpenAlex ID: A5092678723
Angiogenesis in Lung Cancer: Understanding the Roles of Growth Factors
2023 · Yvan Sinclair Ngaha Tchawe, Zhilenkova Angelina V., et al. · Cancers · 55
PDF
Cytokine Profile in Lung Cancer Patients: Anti-Tumor and Oncogenic Cytokines
2023 · Essogmo Freddy Elad, Zhilenkova Angelina V., et al. · Cancers · 30
PDF
Innovative Therapies Targeting Drug-Resistant Biomarkers in Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)
2024 · Moses Owoicho Abah, Deborah Oganya Ogenyi, et al. · International Journal of Molecular Sciences · 10
PDF
Comparative Transcriptomics Study of Curcumin and Conventional Therapies in Translocation, Clear Cell, and Papillary Renal Cell Carcinoma Subtypes
2025 · Moses Owoicho Abah, Deborah Oganya Ogenyi, et al. · International Journal of Molecular Sciences · 6
PDF
Novel Rna-binding Protein Signatures for Predicting Overall Survival in Lung and Kidney Cancer Patients
2026 · Abah Moses Owoicho, Freddy Elad Essogmo, et al.
Serum Markers CA125, CYFRA21-1, FGF2, HE4, β-hCG, and AFP, along with Inflammatory Cytokines (Prolactin, SCF, OPN, and VEGF), in Lung Cancer Diagnosis
2026 · Essogmo Freddy Elad, Yvan Sinclair Ngaha Tchawe, et al. · Indian Journal of Medical and Paediatric Oncology
PDF
Cancer Stem Cells and Angiogenesis: Exploring the Tumor Microenvironment and Therapeutic Strategies in Lung Cancer
2026 · Yvan Sinclair Ngaha Tchawe, Evgeniya A. Kogan, et al. · Current Pharmaceutical Biotechnology
The Thorny Question of Early Diagnosis in Lung Cancer: Should the IP-10 Cytokine be Brought to Trial?
2026 · Yvan Sinclair Ngaha Tchawe, Freddy Elad Essogmo, et al. · Current Cancer Drug Targets
Works count: 8
Citation count: 101
H-index: 4
I10-index: 3
Year
Topic
Type